MIMOSA’s mission is to deliver tissue health imaging technology to drive equity in healthcare.
This equitable approach will save limbs and lives through early detection of tissue compromise.
MIMOSA Pro provides a proactive approach to skin health, allowing clinicians to implement earlier interventions, or even prevent them from being needed at all. Its genesis and development were driven from personal passion and circumstance. As a surgeon, our co-founder, Dr Karen Cross became frustrated at the limited help she could provide as a clinician to help her own Grandfather. Grandfather, living in Newfoundland, lost his leg and ultimately his life due to a lack of access to imaging technology to assess his leg.
As a doctor, living in Toronto, Karen could do nothing to help her mother to help her Grandfather. This experience emboldened her to change the health care system. She could not do this alone and joined forces with an imaging expert and colleague, Dr General Leung, also a MIMOSA co-founder. This partnership delivered the MIMOSA Pro device.
The MIMOSA advantage is that the device is skin pigment, clinical specialty and care setting agnostic, providing equitable access for all clinicians and patients.
While our company is dedicated to a global mindset of equity for all peoples, we're proudly developing our MIMOSA devices out of Toronto, Canada - with staff working remotely all across the country & globe!
“The MIMOSA Pro offers real-time validation, enabling me to gauge the positive impact of our treatment modalities. This insight empowers me to adapt patient care plans proactively, ultimately leading to improved patient outcomes.”
"Having a portable device that could assess tissue compromise and healing potential would be a game changer."
"MIMOSA will revolutionize how Podiatrists/Chiropodists manage patients. It will be a great tool in the fight to prevent diabetic foot and vascular complications!"
"Multispectral and hyperspectral imaging devices are like the modern day TRICORDERS."